04:43 , Dec 15, 2018 |  BioCentury  |  Product Development

O’Day’s expansive task at Gilead

A fresh executive team and a track record of building deep portfolios could allow incoming Gilead Sciences Inc. chairman and CEO Daniel O’Day to do what his predecessors couldn’t: make Gilead a leader outside of...
18:29 , Aug 31, 2018 |  BC Week In Review  |  Company News

Sierra Oncology acquires momelotinib from Gilead

Sierra Oncology Inc. (NASDAQ:SRRA) acquired momelotinib (formerly CYT387) from Gilead Sciences Inc. (NASDAQ:GILD) for $3 million up front and up to $195 million in milestones. Gilead is also eligible for tiered royalties ranging from mid-teens...
22:20 , Jan 6, 2017 |  BioCentury  |  Finance

Tiers of disappointment

A bad year for biotech was closed with an even worse 4Q16 as volatility ahead of the U.S. elections and continued concerns around drug pricing held every market cap band in the red despite a...
18:23 , Nov 18, 2016 |  BC Week In Review  |  Clinical News

Momelotinib: Ph III SIMPLIFY-2 data

Top-line data from the open-label, international Phase III SIMPLIFY-2 trial in 156 patients with MF who were previously treated with but not refractory to Jakafi ruxolitinib showed that once-daily oral momelotinib missed the primary endpoint...
18:23 , Nov 18, 2016 |  BC Week In Review  |  Clinical News

Momelotinib: Ph III SIMPLIFY-1 data

Top-line data from the double-blind, international Phase III SIMPLIFY-1 trial in 432 patients with MF who had not previously been treated with a JAK inhibitor showed that once-daily oral momelotinib met the primary endpoint of...
19:09 , Nov 16, 2016 |  BC Extra  |  Clinical News

Mixed Phase III results for Gilead's momelotinib in myelofibrosis

Gilead Sciences Inc. (NASDAQ:GILD) announced mixed results from two Phase III studies of momelotinib (formerly CYT387) to treat myelofibrosis. The candidate showed non-inferiority to Jakafi ruxolitinib on the SIMPLIFY-1 trial's primary endpoint, but failed to...
02:27 , Feb 12, 2016 |  BC Extra  |  Clinical News

Incyte discontinues Jakafi trials in solid tumors

Incyte Corp. (NASDAQ:INCY) reported 4Q15 and 2015 revenues that beat expectations but fell $6.80 to $65.51 on Thursday after it said it would discontinue all ongoing trials of myelofibrosis drug Jakafi ruxolitinib in solid tumors,...
02:47 , Dec 18, 2015 |  BC Extra  |  Company News

Galapagos finds new filgotinib partner in Gilead

Gilead Sciences Inc. (NASDAQ:GILD) and Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) entered a global co-development and co-commercialization deal for filgotinib ( GLPG0634 ) to treat inflammatory diseases. The partners hope to begin Phase III studies next year...
08:00 , Jan 22, 2015 |  BC Innovations  |  Tools & Techniques

Parsing resistance pathways

Finding mutations that cause resistance to cancer drugs is at best laborious and at worst haphazard, as it involves either one-by-one testing of candidate genes or wholesale screens on resistant cell lines to find agents...
08:00 , Jan 8, 2015 |  BC Innovations  |  Translation in Brief

Uptick for Lyme vaccine

Commercial interest in Lyme disease has all but ground to a halt since the withdrawal of the first vaccine, Lymerix, more than a decade ago, despite a tenfold increase in the U.S. incidence of the...